Catalyst Pharmaceuticals (CPRX) Misses Q4 EPS by 3c, Revenues Beat; Offers FY20 Revenues Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Catalyst Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update
March 16, 2020 5:27 PM EDT-Firdapse® Q4 Net Revenues of $30 Million, FY 19 Net Revenues of $102 Million
-GAAP Net Income of $32 Million for Fiscal Year 2019
-Catalyst Reiterates Net Revenue Guidance in the Range of $135 Million to $155 Million for FY 2020
-Firdapse Supply Chain in Solid Position-Significant Safety Stock
-Company to Host Quarterly Conference Call at 8:30 am ET Tomorrow
CORAL GABLES, Fla., March 16, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:... More
Catalyst Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update
March 16, 2020 5:26 PM EDT-Firdapse® Q4 Net Revenues of $30 Million, FY 19 Net Revenues of $102 Million
-GAAP Net Income of $32 Million for Fiscal Year 2019
-Catalyst Reiterates Net Revenue Guidance in the Range of $135 Million to $155 Million for FY 2020
-Firdapse Supply Chain in Solid Position-Significant Safety Stock
-Company to Host Quarterly Conference Call at 8:30 am ET Tomorrow
CORAL GABLES, Fla., March 16, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:... More
